Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer - PubMed (original) (raw)
. 2014 May 9;344(6184):641-5.
doi: 10.1126/science.1251102.
Simon Turcotte, Alena Gros, Paul F Robbins, Yong-Chen Lu, Mark E Dudley, John R Wunderlich, Robert P Somerville, Katherine Hogan, Christian S Hinrichs, Maria R Parkhurst, James C Yang, Steven A Rosenberg
Affiliations
- PMID: 24812403
- PMCID: PMC6686185
- DOI: 10.1126/science.1251102
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer
Eric Tran et al. Science. 2014.
Abstract
Limited evidence exists that humans mount a mutation-specific T cell response to epithelial cancers. We used a whole-exomic-sequencing-based approach to demonstrate that tumor-infiltrating lymphocytes (TIL) from a patient with metastatic cholangiocarcinoma contained CD4+ T helper 1 (T(H)1) cells recognizing a mutation in erbb2 interacting protein (ERBB2IP) expressed by the cancer. After adoptive transfer of TIL containing about 25% mutation-specific polyfunctional T(H)1 cells, the patient achieved a decrease in target lesions with prolonged stabilization of disease. Upon disease progression, the patient was retreated with a >95% pure population of mutation-reactive T(H)1 cells and again experienced tumor regression. These results provide evidence that a CD4+ T cell response against a mutated antigen can be harnessed to mediate regression of a metastatic epithelial cancer.
Trial registration: ClinicalTrials.gov NCT01174121.
Figures
Fig. 1.. Patient 3737–TIL harbor ERBB2IP mutation–specific CD4+ T cells.
(A to C) Patient 3737–TIL were cocultured with dendritic cells (DCs) transfected with nothing (Mock), green fluorescent protein (GFP) RNA, or the indicated TMG construct encoding the various mutations identified by whole-exomic sequencing.(A) IFN-γ enzyme-linked immunosorbent spot assay at 20 hours. “>“ denotes greater than 500 spots per 1e3 cells. (B and C) Flow-cytometric analysis at 24 hours. Data are gated on live CD3+ cells and, for (C), further gated on CD4+ cells. (D) A CD4+ Vβ22+ clone was co-cultured for 6 hours with autologous B cells pulsed overnight with wild-type (wt) ERBB2IP, mutated (mut) anaplastic lymphoma receptor tyrosine kinase (ALK), or mut ERBB2IP 25-amino acid- long peptides. Flow cytometry was used to detect intracellular IFN-γ production in the CD4+ population. Data are representative of two clones sharing the same TCR-Vβ sequence. (E) Autologous open-repertoire peripheral blood T cells were transduced (Td) with nothing (Mock) or the TCR derived from the Vβ22+ clone and then assessed for reactivity as described in (D). The endogenous Vβ22+ TCR constant regions were swapped with mouse constant regions, allowing for the detection of the introduced TCR using antibodies against the mouse TCRβ constant region (mTCRβ). Plate-bound OKT3 was used as a control in all assays. All data are representative of at least two independent experiments. Error bars are SD.
Fig. 2.. Adoptive transfer ofTILcontainingERBB2IP mutation–reactive T cells.
(A) Flow-cytometric analysis of the TCR-Vβ repertoire of 3737-TIL, gated on live CD4+ or CD8+ T cells. (B) Patient 3737–TIL were cocultured with DCs transfected with TMG-1 or TMG-1 encoding the wt ERBB2IP reversion, and flow cytometry was used to assess OX40 and Vβ22 expression on CD4+ T cells at 24 hours post-stimulation. Plate-bound OKT3 stimulation was used as a positive control. (A) and (B) are representative of at least two independent experiments. (C) IFN-γ enzyme-linked immunosorbent assay on patient 3737 serum samples pre- and post-adoptive cell transfer of 3737-TIL. Error bars are SEM. (D) Tumor growth curves [Response Evaluation Criteria in Solid Tumors (RECIST), sum of maximum diameters] before and after infusion of 3737-TIL. Data are expressed as a change in percent from pretreatment baseline and stratified on lung, liver, and total tumors.
Fig. 3.. Functional phenotype and persistence of ERBB2IP mutation–specific CD4+ T cells.
(A) Patient 3737–TIL were cocultured for 6 hours with autologous B cells pulsed overnight with wt ERBB2IP, mut ALK, or mut ERBB2IP 25–amino acid–long peptides. Flow cytometry was used to assess expression of Vβ22 and to detect intracellular production of IL-2, TNF, and IFN-γ in the CD4+ population. Pie charts display the percentage of Vβ22+ cells that expressed the indicated number of cytokines. Data are representative of at least three independent experiments. (B) TCR-Vβ deep sequencing of 3737-TIL and blood and tumors of patient 3737 at various times pre- and post-adoptive cell transfer with 3737-TIL. Data show the frequency of the two ERBB2IP mutation–specific TCRβ-CDR3 clonotypes. ⊗, not detected.
Fig. 4.. Evidence of tumor regression after treatment with a highly pure population of Vβ22+ ERBB2IP mutation–reactive CD4+ T cells.
(A) Flow-cytometric analysis of the TIL product used for retreatment. Data are gated on live CD3+ T cells (left) and further gated on CD4+ cells (right).(B) Retreatment TIL were cocultured for 6 hours with autologous B cells pulsed overnight with wt or mut ERBB2IP 25–amino acid–long peptides. Flow cytometry was used to detect intracellular TNF production in the CD4+ population. (A) and (B) are representative of at least two independent experiments. (C) Tumor growth curves (sum of maximum diameters) of patient 3737 before and after first and second adoptive cell transfers. The first infusion product consisted of 42.4 billion T cells containing about 25% (10 billion) Vβ22+ ERBB2IP mutation–reactive TH1 cells. The second infusion product consisted of 126 billion T cells containing over 95% (120 billion) Vβ22+ ERBB2IP mutation–reactive TH1 cells. Data are expressed as a change from baseline and stratified on lung, liver, and total tumors. Some target lesions selected in (C) differ from Fig. 2D because only lesions that were present throughout both treatments were selected for measurement.
Comment in
- Cancer immunotherapy: targeting the difference.
Koh S, Bertoletti A. Koh S, et al. J Hepatol. 2014 Nov;61(5):1175-7. doi: 10.1016/j.jhep.2014.06.023. Epub 2014 Jun 30. J Hepatol. 2014. PMID: 24993529 No abstract available. - Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers.
Miamen AG, Gustafson MP, Roberts LR. Miamen AG, et al. Hepatology. 2014 Dec;60(6):2121-4. doi: 10.1002/hep.27442. Epub 2014 Oct 30. Hepatology. 2014. PMID: 25220571 No abstract available.
Similar articles
- Cancer immunotherapy: targeting the difference.
Koh S, Bertoletti A. Koh S, et al. J Hepatol. 2014 Nov;61(5):1175-7. doi: 10.1016/j.jhep.2014.06.023. Epub 2014 Jun 30. J Hepatol. 2014. PMID: 24993529 No abstract available. - Rethinking cancer immunotherapy: Using advanced cancer genetics in immune-mediated eradication of gastrointestinal cancers.
Miamen AG, Gustafson MP, Roberts LR. Miamen AG, et al. Hepatology. 2014 Dec;60(6):2121-4. doi: 10.1002/hep.27442. Epub 2014 Oct 30. Hepatology. 2014. PMID: 25220571 No abstract available. - Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics.
Zanetti M. Zanetti M. J Immunol. 2015 Mar 1;194(5):2049-56. doi: 10.4049/jimmunol.1402669. J Immunol. 2015. PMID: 25710958 Review. - Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy.
Yossef R, Tran E, Deniger DC, Gros A, Pasetto A, Parkhurst MR, Gartner JJ, Prickett TD, Cafri G, Robbins PF, Rosenberg SA. Yossef R, et al. JCI Insight. 2018 Oct 4;3(19):e122467. doi: 10.1172/jci.insight.122467. JCI Insight. 2018. PMID: 30282837 Free PMC article. - Tumor-infiltrating lymphocytes in melanoma.
Lee S, Margolin K. Lee S, et al. Curr Oncol Rep. 2012 Oct;14(5):468-74. doi: 10.1007/s11912-012-0257-5. Curr Oncol Rep. 2012. PMID: 22878966 Free PMC article. Review.
Cited by
- Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.
Shi S, Zhang L, Zheng A, Xie F, Kesse S, Yang Y, Peng J, Xu Y. Shi S, et al. Cancer Immunol Immunother. 2024 Oct 3;73(12):248. doi: 10.1007/s00262-024-03838-8. Cancer Immunol Immunother. 2024. PMID: 39358555 Free PMC article. - Tumor microenvironment and immunology of cholangiocarcinoma.
Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Cadamuro M, et al. Hepatoma Res. 2022;8:11. doi: 10.20517/2394-5079.2021.140. Epub 2022 Mar 10. Hepatoma Res. 2022. PMID: 39301518 Free PMC article. - Identification of immunogenic HLA class I and II neoantigens using surrogate immunopeptidomes.
Tokita S, Fusagawa M, Matsumoto S, Mariya T, Umemoto M, Hirohashi Y, Hata F, Saito T, Kanaseki T, Torigoe T. Tokita S, et al. Sci Adv. 2024 Sep 20;10(38):eado6491. doi: 10.1126/sciadv.ado6491. Epub 2024 Sep 18. Sci Adv. 2024. PMID: 39292790 Free PMC article. - Immunotherapies targeting the oncogenic fusion gene CLDN18-ARHGAP in gastric cancer.
Wang Y, Wang H, Shi T, Song X, Zhang X, Zhang Y, Wang X, Che K, Luo Y, Yu L, Liu B, Wei J. Wang Y, et al. EMBO Mol Med. 2024 Sep;16(9):2170-2187. doi: 10.1038/s44321-024-00120-3. Epub 2024 Aug 20. EMBO Mol Med. 2024. PMID: 39164472 Free PMC article. - [Antitumor Study of Neoantigen-reactive T Cells Co-expressing IL-7 and CCL19 in Mouse Lung Cancer].
Wu D, Li C, Wang Y, He Z, Jin C, Guo M, Chen R, Zhou C. Wu D, et al. Zhongguo Fei Ai Za Zhi. 2024 Jul 20;27(7):504-513. doi: 10.3779/j.issn.1009-3419.2024.106.18. Zhongguo Fei Ai Za Zhi. 2024. PMID: 39147704 Free PMC article. Chinese.
References
- van der Bruggen P, Stroobant V, Vigneron N,Van den Eynde B, “Tumor antigens resulting from mutations,” Cancer Immunity (2013), http://cancerimmunity.org/peptide/mutations/. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous